A. Sinclair Dunlop - 23 Sep 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Sinclair Dunlop
Issuer symbol
APLS
Transactions as of
23 Sep 2024
Net transactions value
+$60,674
Form type
4
Filing time
24 Sep 2024, 16:20:24 UTC
Previous filing
17 Sep 2024
Next filing
03 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $60,674 +4,600 +3.1% $13.19 152,126 23 Sep 2024 Direct
holding APLS Common Stock 100,000 23 Sep 2024 Indirect Owner (Epidarex) F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -4,600 -100% $0.000000 0 23 Sep 2024 Common Stock 4,600 $13.19 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
F2 This option was granted on January 1, 2019 and fully vested.